^
    1d
    Active Surveillance in Older Women With ER+ Breast Cancer (clinicaltrials.gov)
    P=N/A, N=50, Recruiting, University of Pittsburgh
    New trial
    1d
    CATALYST: Choices About Genetic Testing And Learning Your Risk With Smart Technology (clinicaltrials.gov)
    P=N/A, N=50, Completed, Rutgers, The State University of New Jersey | Active, not recruiting --> Completed
    Trial completion
    2d
    Progesterone receptors drive advanced breast cancer phenotypes including circulating tumor-and stem-like cell expansion in the context of ESR1 mutation. (PubMed, bioRxiv)
    We previously showed that PR mediates expansion of cancer stem-like cell (CSC) populations and promotes tamoxifen resistance in nuclear ER/PR transcriptional complexes...The UPR activator ErSO, but not UPR inhibitors, blocked expansion of CSCs in WT as well as Y537S ER + models. Together, our findings demonstrate a critical interplay between PR and mutant ER function and provide insight into PR-driven pathways including hyperactivation of the stress-sensing UPR that can be exploited as potential therapeutic avenues in advanced ER+ breast cancer.
    Journal
    |
    ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • ESR1 mutation
    |
    tamoxifen
    2d
    OPERA-02: Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer (clinicaltrials.gov)
    P3, N=1000, Recruiting, Olema Pharmaceuticals, Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Kisqali (ribociclib) • letrozole • palazestrant (OP-1250)
    2d
    Diagnostic Performance of [18F]FES PET/CT for Axillary LN Metastasis in ER-positive Breast Cancer (clinicaltrials.gov)
    P2, N=71, Completed, Asan Medical Center | Recruiting --> Completed | Trial completion date: Dec 2026 --> Oct 2025 | Trial primary completion date: Aug 2026 --> Oct 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    Oncotype DX Breast Recurrence Score®Test
    3d
    HOPE: A Study to Determine the Efficacy of a Digital Self-management Support Tool to Improve the Quality of Life During Adjuvant HOrmonal Therapy for Patients With Early Breast Cancer (clinicaltrials.gov)
    P3, N=180, Recruiting, Gustave Roussy, Cancer Campus, Grand Paris | Not yet recruiting --> Recruiting | Initiation date: Apr 2025 --> Sep 2025
    Enrollment open • Trial initiation date • HEOR
    3d
    IMOGEN: Contrast-Free Magnetic Resonance Imaging for Breast Disease (clinicaltrials.gov)
    P=N/A, N=1030, Active, not recruiting, Perspectum | Recruiting --> Active, not recruiting | Trial completion date: Sep 2025 --> Dec 2025 | Trial primary completion date: Sep 2025 --> Dec 2025
    Enrollment closed • Trial completion date • Trial primary completion date
    3d
    POP-ELA: A Short-term Preoperative, Evaluating Activity and Safety of Elacestrant Monotherapy as Compared to Elacestrant + Ovarian Function Suppression (LHRH Agonist) in Premenopausal Patients With Stage I-II ER+/HER2- Breast Cancer (clinicaltrials.gov)
    P2, N=140, Recruiting, Gustave Roussy, Cancer Campus, Grand Paris | Not yet recruiting --> Recruiting
    Enrollment open
    |
    ER positive
    |
    Orserdu (elacestrant) • leuprolide acetate for depot suspension
    4d
    EXO1 overexpression induces homologous recombination deficiency and enhances PARP inhibitor sensitivity in ER-positive breast cancer: modulation by N4BP2L2-Mediated restoration. (PubMed, Front Cell Dev Biol)
    Functional assays in both T47D and MCF7 cells demonstrated that co-expression of N4BP2L2 restored HR activity and reduced olaparib sensitivity in EXO1-overexpressing cells. These findings suggest EXO1 overexpression serves as a marker of functional HR deficiency and a potential predictor of PARP inhibitor response, highlighting the EXO1-N4BP2L2 axis as a promising biomarker and therapeutic target, especially for guiding PARP inhibitor use beyond BRCA-mutated tumors.
    Journal • BRCA Biomarker • PARP Biomarker
    |
    ER (Estrogen receptor) • HRD (Homologous Recombination Deficiency) • BRCA (Breast cancer early onset) • EXO1 (Exonuclease 1) • N4BP2L2 (NEDD4 Binding Protein 2 Like 2)
    |
    ER positive • HRD • BRCA mutation
    |
    Lynparza (olaparib)
    5d
    NSUN7 Suppression Reduces Metastatic Potential and Restores Sensitivity to 4-OH Tamoxifen in Resistant MCF-7 Cells. (PubMed, Anticancer Res)
    Our study identified that NSUN7 regulates key oncogenic pathways associated with tamoxifen resistance and metastasis. Its suppression enhanced tamoxifen sensitivity and reduced metastatic potential, collectively highlighting NSUN7 as a novel driver of tamoxifen resistance and a potent therapeutic target in estrogen receptor-positive breast cancer.
    Journal
    |
    ER (Estrogen receptor) • YAP1 (Yes associated protein 1) • AJUBA (Ajuba LIM Protein) • BASP1 (Brain Abundant Membrane Attached Signal Protein 1) • NOP2 (NOP2 Nucleolar Protein) • SKP2 (S-phase kinase-associated protein 2) • TIMP3 (TIMP Metallopeptidase Inhibitor 3)
    |
    ER positive
    |
    tamoxifen
    6d
    Outcomes for ER-positive CHEK2 c.1100delC breast cancer patients compared with breast cancer patients without the variant. (PubMed, Breast)
    In our study, with more recent years of diagnosis and treatment, we found no difference in prognosis, as opposed to previous studies. Further research is needed to validate our findings.
    Journal
    |
    ER (Estrogen receptor) • CHEK2 (Checkpoint kinase 2)
    |
    ER positive